61 results about "Multidrug resistant Pseudomonas aeruginosa" patented technology

The invention provides isolated polypeptide and nucleic acid sequences derived from Pseudomonas aeruginosa that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

The invention relates to a pseudomonas aeruginosa bacterial strain (serial number being CB-4) and a crude toxin preparation method thereof, which belong to the field of applying microorganisms to agricultural plant protection. The strain crude toxin has a strong inhibition effect for weeds including crab grass, amaranthus retroflexus, barnyard grass, green bristlegrass, rhodes grass and the like, and in particular respectively has IC50 reaching 299.25mg.L<-1> and 210.11mg.L<-> to seed germination root stalk length, and has the characteristics of being safe and environment-friendly, harmless to crops and the like.

Improved antibodies are provided selected from human, dual-specific, chimeric or humanized antibodies, wherein said human chimeric and humanized antibodies specifically bind to flagellin type A or type B of P. aeruginosa, and said dual-specific antibodies specifically binds to flagella type A and type B of Pseudomonas aeruginosa, and said antibodies are protective against infection caused by P. aeruginosa. These antibodies as well as pharmaceutical composition comprising them are useful for the treatment of indications caused by P. aeruginosa infection.

The invention relates to a Pseudomonas aeruginosa and its application. The microbial preservation number of Pseudomonas aeruginosa QHH S1-27-2 is CCTCC NO:M2012468. The Pseudomonas aeruginosa is applied to high salinity reservoir microbial oil recovery. The Pseudomonas aeruginosa can growth with crude oil as a sole carbon source, and a biological surfactant component in the metabolites of the Pseudomonas aeruginosa can reduce oil-water interfacial tension, so the effective permeability of reservoirs is increased to a certain extent, the oil displacement efficiency of injected water is improved, and the crude oil recovery rate is improved.

The invention discloses pseudomonas aeruginosa DGNK-JL2. The pseudomonas aeruginosa DGNK-JL2 is collected by a Guangdong Microbial Culture Collection Center, which is located at fifth floor of building 59# of yard 100#, middle Xianlie road, Guangzhou, Guangdong 510075, on Aug 22, 2019 and has the collection number of GDMCC NO: 60748. A strain of phosphate solubilizing bacteria, i.e., the pseudomonas aeruginosa DGNK-JL2 is separated and screened out from traditional Chinese medicine decoction dreg compost and is subjected to identification and biological control action tests, so that a strain for preparing efficient biofertilizers is reserved, and the sustainable development of ecological agriculture is boosted; and by employing the pseudomonas aeruginosa DGNK-JL2 disclosed by the invention, the content of available phosphorus in soil can be increased by 8.6 times to the maximum, and fermentation broth of the strain DGNK-JL2 disclosed by the invention has a certain antagonistic action on pepper anthracnose and bitter melon blight.

The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Pseudomonas aeruginosa, and methods of using that bacteriophage, and / or progeny or derivatives derived therefrom, to control the growth of Pseudomonas aeruginosa in various settings.

The invention discloses a pseudomonas aeruginosa and an application. The pseudomonas aeruginosa CP1 is collected by China Centre for Type Culture Collection, wherein the collection number is CCTCC NO: 2015197, and the collection date is April 6, 2015. The strain is used for a denitrification treatment for nitrogen-containing wastewater or used for an aerobic denitrification denitration treatment for NOx smoke or waste gas. In case of no impressed current, the optimal culture condition of the strain comprises a temperature of 30-40 DEG C and C / N of not less than 12. The strain is still capable of maintaining an efficient nitrate degradation process under an aerobic condition. However, the strain is capable of achieving a removal rate of 99.01% or above for nitrate nitrogen with an initial concentration of 250mg / L within 16 hours in the case that the C / N is reduced to 4-6 under the current simulation of 10mA, and hardly generates nitrate accumulation.

The present invention relates to a bacteriophage PA1Φ belonging to family Siphoviridae, characterized that it is capable of killing one or more bacteria strains selected from a group comprising Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus homonis, Shigella sonnei, Listeria monocytogenes and Streptococcus pneumonia, and contains a full-length genome of SEQ ID NO: 1.According to the present invention, the bacteriophage PA1Φ can be used to kill said bacteria and reduce the same effectively. Also, it can be used to remove biofilms generated by said bacteria. Especially, this bacteriophage is applicable for medical industry, food industry, biotechnology and the like, because it is a sort of virus that kills host bacteria without any adverse effect on human, animals and so on. In addition, this bacteriophage can kill noxious bacteria on target sites or target supports without any problem related with resistance development of bacteria.

The invention discloses design of polypeptides specifically binding to immune protein of a pseudomonas aeruginosa type VI secretion system, and validation of antibacterial activity of the polypeptides. The invention first protects a polypeptide, and the polypeptide is shown by a sequence 3 or a sequence 4 in a sequence table. The gene encoding of the polypeptides also falls within the scope of protection of the invention. The invention also protects the application of the polypeptides: binding to the immune protein in the bacteria type VI secretion system; enriching the immune protein in the bacteria type VI secretion system; detecting the immune protein in the bacteria type VI secretion system. The functional short peptides provided by the invention can bond to the immune protein togetherwith effector protein in a competitive way, so that the interaction between TplE and TplEi is destroyed, and the effector protein is further enabled to break down the cell membranes of bacteria and cause the bacteria to die; therefore, the design is a most potent novel antibacterial strategy taking the T6SS effector protein as a target, and a new direction is provided for the treatment of clinically drug-resistant strains.

The invention provides a gene chip for detecting an important drug resistant gene of pseudomonas aeruginosa and a kit thereof. The gene chip comprises a solid-phase carrier and an oligonucleotide probe fixed on the solid-phase carrier, wherein the probe comprises a DNA fragment or a complementary DNA fragment thereof selected from carb, tem, imp, oxa group I, oxa group II, aac (6')-Ib, aac (6')-II, aac (3')-I, aac (3')-II, aadB and a bacterium 16S rRNA gene. The gene chip and the detecting kit can achieve the aim of simultaneously detecting the 10 drug resistant genes of the pseudomonas aeruginosa, have the characteristics of high pertinence, high specificity, high sensitivity, high detecting speed, high repeatability, and the like and are suitable for a hospital, a disease preventing control mechanism and other clinical laboratories to carry out drug resistant gene detection and drug resistance monitoring on the pseudomonas aeruginosa.

A method of identifying a bacteria, such as Pseudomonas aeruginosa, in a sample, includes providing a sample suspect of comprising a bacteria to be identified, exposing the sample to an antibody specific for a lipoprotein of the bacteria and an agglutination reagent, allowing the sample to react with the antibody and the agglutination reagent, wherein the presence of the bacteria is indicated if an agglutination occurs. A kit for testing the presence of a bacteria, such as Pseudomonas aeruginosa, includes an agglutination reagent and an antibody specific for a lipoprotein of the bacteria.

An object of the present invention is to provide a protein or peptide antigen and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa. According to the present invention, there is provided a protein or peptide derived from Pseudomonas aeruginosa outer membrane protein PA0427 and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa.

The invention provides pseudomonas aeruginosa. A classification name of the pseudomonas aeruginosa is pseudomonas aeruginosa T1-3, the pseudomonas aeruginosa is preserved in the Common Microorganism Center of the China Committee for Culture Collection of Microorganisms, the address is the Institution of Microbiology of the Chinese Academy of Sciences in the No.3 yard of the No.1 Beichen West Road in the Chaoyang district of Beijing, the postal code is 100101, a preservation number is CGMCC No.10433, and a preservation date is January 23, 2015. The pseudomonas aeruginosa has the advantages that excellent prevention and treatment effects can be realized by the pseudomonas aeruginosa for diversified diseases of plants such as corn, cow peas, chili, cabbage and leek, and the pseudomonas aeruginosa has wide antibacterial spectra; the pseudomonas aeruginosa is high in reproduction speed and stress resistance and favorable for production application, and can be artificially cultivated, and cultivation conditions are simple; the pseudomonas aeruginosa is free of pathogenicity to people and livestock, is safe and effective and accordingly has an excellent development prospect.

The invention discloses a purification method of pseudomonas aeruginosa (PA) recombinant subunit genetic engineering vaccine protein Vac11. The protein is recombined and fused by the active functional fragments of pseudomonas aeruginosa antigen molecules and obtained through escherichia coli genetically engineered bacterium expression. High-pressure bacterium breaking, GST affinity chromatography, PP enzyme digestion, Q HP chromatography, G 25 chromatography, Q HP chromatography and the like are performed on genetically engineered bacteria to obtain the high-purity pseudomonas aeruginosa (PA) recombinant subunit genetic engineering vaccine protein Vac11. The purification method has the advantages that the method is simple in process, easy in amplification and good in repeatability, the obtained target protein is high in purity, and animal experiments prove that the protein can effectively stimulate a body to generate humoral immune response and is good in immune protection effect.

The invention relates to an application of a Pseudomonas aeruginosa polyclonal antibody during a salmonella separation process. Acceding to the invention, the polyclonal antibody is used for detecting salmonella, the method comprises the following steps: preparing the polyclonal antibody of interference bacteria-Pseudomonas aeruginosa during the salmonella separation process, purifying by a saturation ammonium sulfate method, adding the purified antibody in a selective enrichment broth during the salmonella separation process, and reacting for 12 hours at the temperature of 37 DEG C and then carrying out subsequent separating culture.

The invention discloses a method for purifying pseudomonas aeruginosa (PA) recombinant subunit genetic engineering protein vaccine Vac 14. The Vac 14 protein is obtained in the mode that active functional fragments of pseudomonas aeruginosa antigen molecules are recombined and confused, and escherichia coli genetically engineered bacterium expression is conducted. Technologies including high pressure bacterium breaking, GST affinity chromatography, PP enzyme restriction enzyme digestion, SPHP chromatography, G25 chromatography, Q HP chromatography and the like are adopted for genetic engineering bacteria, and the high-purity pseudomonas aeruginosa (PA) recombinant subunit genetic engineering protein vaccine Vac 14 is obtained. The method is simple and fast in purifying process, easy to amplify and good in repeatability, the obtained target protein is high in purity, and it is proved by animal tests that a mechanism can be effectively stimulated to generate high humoral immune response and a good immune protective effect.

The present invention is drawn to conjugates and vaccine compositions comprising a Pseudomonas flagellin or an antigenic fragment or derivative thereof linked to one or more Klebsiella surface polysaccharide antigens, such as Klebsiella pneumoniae O5 polysaccharide from serovars O1, O2a, O2a,c, O3, O4, O5, O7, O8 and 012. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions.

The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Pseudomonas aeruginosa, and methods of using that bacteriophage, and / or progeny or derivatives derived therefrom, to control the growth of Pseudomonas aeruginosa in various settings.

Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.

Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype A and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.

The invention discloses a pseudomonas aeruginosa detection kit and an application thereof. The kit comprises upstream primers including a sequence indicated by SEQ ID 01, downstream primers including a sequence indicated by SEQ ID 02, a selective bacterial enriching liquid, a PCR reagent, a positive contrast, a negative contrast and a blank. The specific primers in the kit are designed for o-antigen acetylase gene of pseudomonas aeruginosa, and effectively distinguish between the pseudomonas aeruginosa and common pathogenic bacteria ( including other 19 species of pseudomonas ). The quick, highly reliable detection for pseudomonas aeruginosa is accomplished.

The invention discloses a drug for relieving pseudomonas aeruginosa keratitis. Bacterial proliferation and virulence expression of pseudomonas aeruginosa in the cornea are inhibited by applying a beta2 adrenergic receptor inhibitor, the number of neutrophils infiltrated in the cornea and the expression of inflammatory factors are decreased to reduce the severity of the keratitis. The drug can inhibit bacterial proliferation in the cornea and improve inflammatory reaction in the cornea, thereby reducing inflammatory reaction of the pseudomonas aeruginosa keratitis, and is a novel drug for relieving the pseudomonas aeruginosa keratitis.

The present invention relates in general to the detection of antibiotic resistance determinants in Pseudomonas aeruginosa (P. aeruginosa). The present invention discloses a micro-array for the detection of antibiotic resistance determinants and mutations in said organism, a method for the detection of said determinants and a kit. This micro-array concept offers the rapid sensitive and specific identification of antibiotic resistance profiles.

This invention provides methods of treating patients having a Staphylococcus infection where the patient also has a low level of Pseudomonas aeruginosa. The methods comprise administering an antagonist of the Pseudomonas Type III Secretion System, e.g., an anti-PcrV antibody antagonist.

The invention discloses a screening culture medium applicable to extensively drug-resistant pseudomonas aeruginosa and a preparation method, and relates to the technical field of microorganism. The screening culture medium comprises a basal culture medium, nutrient substance promoting the growth of the pseudomonas aeruginosa, antibiotic used for the detection of the multidrug resistant pseudomonas aeruginosa and distilled water. The method comprises the following steps: preparing the nutrient substance promoting the growth of the pseudomonas aeruginosa, adding the nutrient substance into the basal culture medium, and performing autoclaving, so as to obtain an initial culture medium; adding the antibiotic used for the detection of the multidrug resistant pseudomonas aeruginosa into the initial culture medium at a room temperature to 60 DEG C after sterilization, performing uniformly mixing, separately injecting the initial culture medium into different holes of a layout plate, cooling at a room temperature, so as to obtain the screening culture medium applicable to the extensively drug-resistant pseudomonas aeruginosa. The screening culture medium has the advantages that the detection time is reduced, the sensitivity is high and the preparation method is simple and convenient.

An object of the present invention is to provide a protein or peptide antigen and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa. According to the present invention, there is provided a protein or peptide derived from Pseudomonas aeruginosa outer membrane protein PA5158 and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa.

The invention discloses application of recombinant klebsiella pneumoniae in producing 1,3-propylene glycol and particularly discloses a method for improving the yield of the 1,3-propylene glycol by using mexF gene in heterologously-expressed pseudomonase aeruginosa of the klebsiella pneumoniae and application thereof, and belongs to the technical field of genetic engineering. According to the method disclosed by the invention, by applying a genetic engineering method, plasmid with the mexF gene in the pseudomonas aeruginosa is transferred to the klebsiella pneumoniae for enhancing the transportation efficiency of the klebsiella pneumoniae to short chain alcohol, so that the yield of the 1,3-propylene glycol is improved. The yield of the 1,3-propylene glycol reaches as high as 74g / L by carrying out fed-batch fermentation on arecombinant strain in a 5L fermentation tank. The method has the advantages that the transportation capacity of the klebsiella pneumoniae to the 1,3-propylene glycol is successively improved, provides a novel method for improving the yield of the 1,3-propylene glycol and provides a new idea for breeding high-yielding strains of the 1,3 propylene glycol.